Introduction {#S0001}
============

Lung cancer remains the leading cause of cancer-related mortality worldwide.[@CIT0001] Non-small cell lung cancer (NSCLC) comprises 80% of lung cancer. Fifty percent of lung cancer patients are diagnosed with locally advanced or metastatic disease, at which point surgical resection might not be preferred.[@CIT0002] In recent years, with the development of genomic characterizations, several molecular-targeted therapies have brought great clinical benefits for patients harboring driver gene mutations.[@CIT0003] For example, tyrosine kinase inhibitors targeting epidermal growth factor receptor *(EGFR)* driver mutations, anaplastic lymphoma kinase (*ALK)* rearrangement, repressor of silencing 1 (*ROS1)* fusions, and neurotrophic tyrosine kinase (*NTRK)* fusions have been approved by the Food and Drug Administration (FDA) for NSCLC patients harboring corresponding mutations. Furthermore, other oncogenic alterations, including *BRAF* V600E, *RET, MET and HER2* have also been identified in subtypes of NSCLC and therapies targeting these mutations are underlying exploring.[@CIT0004],[@CIT0005]

Among these oncogenes, *HER2*, also known as *ErbB2*, a sort of *ErbB* receptor tyrosine kinase, is activated by homodimerization or heterodimerization with other *ErbB* family members, especially EGFR.[@CIT0006],[@CIT0007] The activated *HER2* can subsequently activate downstream signaling molecules, including PI3K-AKT and MEK-ERK pathways. Oncogenic activation of *HER2* mutations occurs in 1--4% of NSCLC, accumulating in female non-smokers with advanced lung adenocarcinoma.[@CIT0008]--[@CIT0010] *HER2* exon 20 in-fame insertion, especially A775_G776insYVMA, is the most common mutant form (over 80%).[@CIT0011]

Anti-HER2 agents have been investigated in NSCLC for a long time. In Phase II randomized study, no difference of clinical benefit was observed between gemcitabine with or without trastuzumab in *HER2*-positive NSCLC.[@CIT0012] Aado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate, is composed of an anti-HER2 humanized antibody (trastuzumab) and microtubule polymerization inhibitors showed limited efficacy in *HER2*-positive NSCLC patients.[@CIT0013] However, in another Phase II study evaluating the efficacy of TDM1 in *HER2*-mutated NSCLC patients, the corresponding objective response rate (ORR) was 44% and the median progression-free survival (PFS) was 5 months.[@CIT0014] These results suggested that *HER2* mutation in the protein kinase domain instead of *HER2* amplification may be sensitive to anti-HER2 agents.

Afatinib, an oral ErbB family blocker, exhibits antitumor efficacy via downregulating the phosphorylation of HER2 and EGFR.[@CIT0015] In previous reports, afatinib therapy has exhibited promising results and manageable profile in *HER2* exon 20 in-fame insertion, such as A775_G776insYVMA, P780_Y781ins GSP and A775_G776lnsVAG.[@CIT0016]--[@CIT0019] In 2013, Mazieres and coworkers retrospectively identified 65 NSCLC harboring *HER2* exon 20 insertion. Favorable results showed that the disease control rate (DCR) in patients administrated afatinib reached up to 100% (n=4).[@CIT0009] In a retrospective European EUHER2 cohort, nine patients with *HER2* exon 20 insertion were treated with afatinib. The corresponding ORR and median PFS were 18.2% and 3.9 months, respectively.[@CIT0020] In a global NPU program, the real-world data on the use of afatinib treatment also showed the patients with *HER2*-mutated NSCLC harboring *HER2* exon 20 A775_G776insYVMA insertion, achieved the best benefit.[@CIT0021] Besides of HER2 exon 20 insertion mutations, case-reports also demonstrated the efficacy of afatinib in NSCLC patients harboring *HER2* point mutations like G776L, N813D, G660R, V659E and S310Y, regardless of the mutation domain (kinase domain, transmembrane domain or extracellular domain).[@CIT0016],[@CIT0022]--[@CIT0025] These results show promising efficacy of afatinib in NSCLC patients harboring *HER2* point mutations. However, the efficacy of afatinib in other rare *HER2* mutations have been not explored.

Herein, we present a case of NSCLC patient harboring a rare *HER2* R896G mutation, who responded to afatinib.

Case Presentation {#S0002}
=================

A 63-year-old Chinese male with a long smoking history was diagnosed with squamous cell lung carcinoma in December 2017. The tumor node metastasis (TNM) classification of this patient was T3N2M1. The patient had multiple hepatic metastatic lesions. The Eastern Cooperative Oncology Group (ECOG) performance status score of the patient was 0. His initial tumor biopsy was negative for EGFR mutations or ALK rearrangement according to the results from an amplification refractory mutation system-polymerase chain reaction (arms-PCR) assay. The patient was first treated with carboplatin (495 mg, day 1) and gemcitabine (1.6 g, day 1 and day 8). After the failure of the first-line treatment in May 2018 due to progressive disease (PD), the patient received nidaplatin (40 mg once a day, day 1--3) and docetaxel (120 mg, day 1) as a second-line treatment and relapsed in July 2018.

To seek for potential treatment opportunities, circulating tumor DNA extracted from blood was subjected to DNA sequencing analysis using a cancer-gene panel with next-generation sequencing (NGS) as previously reported.[@CIT0026] The sequencing results showed that the patient had a *HER2* exon 22 R896G mutation with an allelic fraction of 50.77% ([Figure 1](#F0001){ref-type="fig"}). Since the immunohistochemistry (IHC) detection for HER2 expression was not routinely carried out in the pathology department of our hospital, IHC examination was not performed for the patient at that time.Figure 1The integrative genomics viewer snapshot of *HER2* R896G by next-generation sequencing.

Thus the patient started to receive afatinib (40 mg/day) according to the NGS results in July 7, 2018. After the treatment of 2 months, the computed tomography (CT) scan showed that the maximal tumor diameter in the target lesions decreased from 5.61 cm to 3.34 cm with a decrease of 40.5% ([Figure 2A](#F0002){ref-type="fig"} and [B](#F0002){ref-type="fig"}). According to the response evaluation criteria in solid tumors (RESIST 1.1), this patient was evaluated as a radiological partial response (PR). Comparing the CT scan in [Figure 2B](#F0002){ref-type="fig"}, the maximal tumor diameter in ([Figure 2C](#F0002){ref-type="fig"} and [2D](#F0002){ref-type="fig"}) increased from 3.31 cm to 3.64 cm (3.78 cm) with an increase of 9.0% (13.2%). Although the tumor increased, this patient was evaluated as a radiological stable disease (SD) according to the RESIST 1.1. As for the hepatic metastatic lesions, the maximal tumor diameter of the biggest metastasis before afatinib treatment was 3.2 cm ([Figure 3A](#F0003){ref-type="fig"}). After afatinib treatment, the CT image suggested that the metastasis lesion had been reduced significantly and become unclear ([Figure 3B](#F0003){ref-type="fig"}--[E](#F0003){ref-type="fig"}). The treatment-related adverse events associated with afatinib were grade 1 paronychia and grade 1 stomatitis without treatment interruption, which occurred during the first month of afatinib treatment and relieved without any treatment. Moreover, he got fever and obstructive pulmonary disease during the treatment, but it was hard to judge whether these symptoms were related with afatinib. Until September 2019, the latest return visit, no progressive disease had been observed in the patient ([Figure 2E](#F0002){ref-type="fig"}). The progression-free survival is more than 14 months. Thus far, the afatinib treatment is ongoing.Figure 2Computed tomography (CT) scans revealed the tumor response to afatinib. (**A**) The progressive disease status of lung lesion before afatinib treatment. (**B**) CT of the chest showing partial response after 2 month of afatinib treatment. CT of the chest showing no progressive disease after (**C**) 7 months, (**D**) 11 months and (**E**) 14 months of afatinib treatment.Figure 3Computed tomography (CT) scans revealed the changes of the metastatic lesion (**A**) before afatinib treatment and after (**B**) 2 month, (**C**) 7 months, (**D**) 11 months and (**E**) 14 months of afatinib treatment. The red dash circle in (**A**) represents the biggest metastasis lesion.

This study was approved by the Medical Ethics Committee of the Taizhou Hospital of Wenzhou Medical University. Written informed consent had also been provided by the patient for publishing the case details and accompanying images in the case study.

Discussion {#S0003}
==========

In this case, we discussed a 63-year-old male diagnosed with stage IV squamous cell lung cancer. After the failures of two lines of chemotherapy, the patient was found to harbor a *HER2* R896G mutation by a next-generation sequencing of circulating tumor DNA. Radiologically, the patient responded very well to afatinib, suggesting that afatinib may a potential treatment option for NSCLC patients harboring *HER2* R896G mutation.

In previous reports, NSCLC patients harboring *HER2* mutations are mainly female non-smokers with the adenocarcinoma subtype.[@CIT0008] Among these patients with *HER2*-mutated NSCLC, the most common *HER2* mutations are exon 20 in-fame insertion, such as A775_G776insYVMA and P780_Y781ins GSP.[@CIT0011] Besides, some mutations in *HER2* kinase domain are also documented, such as L755P, V773M, G776L E812K, N813D, R814H and Q828R.[@CIT0014],[@CIT0022],[@CIT0027] Though rarely occurring, the mutations in transmembrane domain (G660R and V659E)[@CIT0023] and extracellular domain (S310Y)[@CIT0024],[@CIT0025] have also been identified. To the best of our knowledge, *HER2* exon 22 R896G mutation has never been identified and reported. *HER2* exon 22 R896G is located in the kinase region; thus, it is reasonable to question whether it is an activating mutation. *HER2* R896C was ever recognized in an individual with breast carcinoma.[@CIT0028] Moreover, a preclinical experiment demonstrated that point mutation at codon 896 could increase the phosphorylation of phospholipase C γ.[@CIT0028] Based on these evidences mentioned above, afatinib was administered to treat the patient.

Afatinib, an oral ErbB family blocker, has been reported to display promising results in NSCLC with *HER2* mutations, including A775_G776insYVMA, P780_Y781ins GSP, G776L and N813D.[@CIT0016],[@CIT0017],[@CIT0022] A few cases suggested that the patients with NSCLC harboring the mutations in transmembrane domain (G660R and V659E)[@CIT0023],[@CIT0029] and extracellular domain (S310Y)[@CIT0024],[@CIT0025] also can generate clinical benefit from afatinib therapy. In our case, a similar promising result and manageable toxicity profile were observed. These results suggested that afatinib may be effective in *HER2* R896G.

To be mentioned, the patient received arms-PCR for EGFR and ALK sequencing when diagnosed. However, no driver mutations were identified. After progression, *HER2* R896G was identified by a NGS of circulating tumor DNA, which benefited from the distinguishing features of NGS. NGS can not only uncover various types of known and unknown mutation, including single nucleotide variant (SNV), insertion, copy number variation (CNV), etc., but also do multi-genic detection in a panel, which may be helpful to give more mutation information than arms-PCR.[@CIT0030] NGS for circulating tumor DNA detection is becoming a very important role in both clinical and research applications, because of its low cost, high accuracy, high throughput and rich information content and is recommended by National Comprehensive Cancer Network in NSCLC patients when tissues are not available.

Conclusion {#S0004}
==========

Overall, we reported the first case of a patient with NSCLC harboring a rare *HER2* R896G mutation, who responded to afatinib. Based on this finding, afatinib might be considered as an optimal treatment for NSCLC harboring *HER2* R896G mutation. Further analysis of the efficacy of HER2-targeted therapies in such cases will lay the foundation for developing optimized therapeutic regimen for NSCLC patients with uncommon driver gene mutations.
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